NCT01995071View on ClinicalTrials.gov

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Chronic Hepatitis CHepatitis C VirusCompensated Cirrhosis
Interventions
DRUG

ABT-493

Tablet

DRUG

ABT-530

Tablet

DRUG

ABT-450/r/ABT-267, ABT-333

Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

DRUG

Ribavirin (RBV)

Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY